China has the greatest burden of hepatitis C virus (HCV) in the world. Chronically infected HCV patients are at a high risk of developing cirrhosis, liver cancer, and early death if left untreated. Most HCV patients in China are prescribed older generic agents such as interferon-α-2a, interferon-α-2b, pegylated interferon-α-2a (Peg-Intron), and sofosbuvir (Sovaldi). However, we expect that the recently launched coblopasvir (Beijing Kawin Biotechnology), ravidasvir (Ascletis Biotechnology’s Asclevir), sofosbuvir / velpatasvir FDC (Gilead Sciences’ Epclusa) in addition to the emerging therapies―alfosbuvir (Daiichi Sankyo), seraprevir (CStone pharmaceuticals), and ropeginterferon alfa-2b (PharmaEssentia)—set to launch for HCV during the forecast period, will result in significant growth of the Chinese HCV market over the 2021-2031 period. However, the need for additional effective therapies will remain high, representing a lucrative commercial opportunity for developers. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly incentivized to enter the HCV market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 infectious disease specialists.
Diagnosed prevalence of HCV in urban versus rural China. Clinically and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key HCV therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
PR / Phase III: 4 drugs. Phase II: 1 drug. Coverage of select early-phase products.